Clinical Trial

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Study acronym: ALLight
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-07-31; most recent amendment 2026-07-10.
Status change: Not Yet Recruiting → Recruiting 2025-12-08
Trial Details
NCT Number NCT07109219
Lead Sponsor AstraZeneca
Collaborators: Fortrea
Conditions B-cell Acute Lymphoblastic Leukemia (B-ALL)
Enrollment 83 participants
Start Date 2025-11-12
Primary Completion 2028-04-28 (estimated)
Study Completion 2028-07-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-13